Nigel Mackman

Tissue-specific hemostasis: role of tissue factor.

Tissue factor and factor VIIa: understanding the molecular mechanism.

Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury.

Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.

Bleeding hearts.

Cardiovascular disease in women.

Venous thromboembolism: risk factors, biomarkers, and treatment.

Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay.

The role of tissue factor and factor VIIa in hemostasis.

On the trail of microparticles.

Role of tissue factor in cancer.

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.

Tissue factor: past, present, and future.

DVT: a new era in anticoagulant therapy.

Wound healing in hemophilia B mice and low tissue factor mice.

Cellular sources of tissue factor in endotoxemia and sepsis.

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.

Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice.

Tissue factor and thrombosis: The clot starts here.

Elevated tissue factor expression contributes to exacerbated diabetic nephropathy in mice lacking eNOS fed a high fat diet.

Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.

Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis.

Balancing clotting.

Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays.

MPs or ICs?

Protease-activated receptors and myocardial infarction.

Microparticles in hemostasis and thrombosis.

Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner.

Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity.

Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.

Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.

Blood coagulation and blood vessel development: is tissue factor the missing link?

Comment on "tissue factor-dependent chemokine production aggravates experimental colitis".

Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.

Effect of PAR-2 Deficiency in Mice on KC Expression after Intratracheal LPS Administration.

Myeloid cell tissue factor does not contribute to venous thrombogenesis in an electrolytic injury model.

Tissue factor in health and disease.

Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin.

Mouse models, risk factors, and treatments of venous thrombosis.

PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.

Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque.

Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.

Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.

β-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells.

Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease.

New insights into the mechanisms of venous thrombosis.

P2X7 regulation of macrophage tissue factor activity and microparticle generation.

Dysregulated coagulation associated with hypofibrinogenaemia and plasma hypercoagulability: implications for identifying coagulopathic mechanisms in humans.

Role of tissue factor in atherothrombosis.

Hepatocyte tissue factor activates the coagulation cascade in mice.

Platelet ITAM signaling is critical for vascular integrity in inflammation.

Microvesicles as risk markers for venous thrombosis.

PAR-1 contributes to the innate immune response during viral infection.

Hyperlipidemia, tissue factor, coagulation, and simvastatin.

Coagulation, protease-activated receptors, and viral myocarditis.

Protease activated receptor-2 contributes to heart failure.

The antithrombotic effects of statins.

Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.

Circulating microparticle tissue factor activity is increased in patients with cirrhosis.

Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Multiple roles of the coagulation protease cascade during virus infection.

Roles of PAR1 and PAR2 in viral myocarditis.

Regulation of tissue factor gene expression in monocytes and endothelial cells: Thromboxane A2 as a new player.

Factor XIII activity mediates red blood cell retention in venous thrombi.

Fas-induced apoptosis increases hepatocyte tissue factor procoagulant activity in vitro and in vivo.

New targets for atherothrombosis.

Inactivation of factor VIIa by antithrombin in vitro, ex vivo and in vivo: role of tissue factor and endothelial cell protein C receptor.

PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression.

Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.

Protective and pathological roles of tissue factor in the heart.

Role of tissue factor in Mycobacterium tuberculosis-induced inflammation and disease pathogenesis.

Excess of heme induces tissue factor-dependent activation of coagulation in mice.

RASA3 is a critical inhibitor of RAP1-dependent platelet activation.

Extracellular vesicles, tissue factor, cancer and thrombosis - discussion themes of the ISEV 2014 Educational Day.

A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection.

Tissue Factor and Atherothrombosis.

Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm.

Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury.

Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic syndrome).

IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells.

Microvesicle Tissue Factor Activity and Interleukin-8 Levels are Associated with Mortality in Patients with Influenza A/H1N1 Infection.

Thrombin-independent contribution of tissue factor to inflammation and cardiac hypertrophy in a mouse model of sickle cell disease.

Editorial Commentary: Tissue factor expression by the endothelium: Coagulation or inflammation?

The Clot Thickens in Atherosclerosis.

Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays.

Myeloid tissue factor does not modulate lung inflammation or permeability during experimental acute lung injury.

Tissue factor deficiency increases alveolar hemorrhage and death in influenza A virus-infected mice.

Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.

Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.

CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in Mice.

Venous thrombosis.

Mouse models of venous thrombosis are not equal.

Complying With the National Institutes of Health Guidelines and Principles for Rigor and Reproducibility: Refutations.

Protective and detrimental effects of neuroectodermal cell-derived tissue factor in mouse models of stroke.

Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group.

A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice.

Corrigendum to 'Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer", [Thromb. Res. 141 (2016) 39-48].

Corrigendum to "Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays" [Thromb. Res. 139 (2016) 90-97].

Letter to Editor response: Endothelial cell tissue factor and coagulation.

Protease-Activated Receptor 1 Enhances Poly I:C Induction of the Antiviral Response in Macrophages and Mice.

Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Erratum to "A combined deficiency of tissue factor and PAR-4 is associated with fatal pulmonary hemorrhage in mice" [Thromb. Res. 146 (2016) 46-50].

Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.

Tissue Factor: Catch Me If You Can!

Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy.

Methodological Guidelines to Study Extracellular Vesicles.

A monocyte-TNF-endothelial activation axis in sickle transgenic mice: Therapeutic benefit from TNF blockade.

Thrombin promotes diet-induced obesity through fibrin-driven inflammation.

Cancer-associated pathways and biomarkers of venous thrombosis.

Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo.

Mouse models of cancer-associated thrombosis.

Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease.

Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo.

Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis.

Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients.

Comparison of microvesicle tissue factor activity in non-cancer severely ill patients and cancer patients.

Platelet Signaling Pathways and New Inhibitors.

PAR2 (Protease-Activated Receptor 2) Deficiency Attenuates Atherosclerosis in Mice.

Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.

Tissue factor and oxidative stress.

Response by Daugherty et al to Letter Regarding Article, "Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies: A Statement From the Council".

The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.

The uremic solute-AHR-tissue factor axis in vascular cells, mouse models and thrombosis in chronic kidney disease patients.

Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.

Neutrophils, NETs, and immunothrombosis.

Reporting Sex and Sex Differences in Preclinical Studies.

Low extracellular vesicle-associated tissue factor activity in patients with persistent lupus anticoagulant and a history of thrombosis.

mTOR kinase inhibition reduces tissue factor expression and growth of pancreatic neuroendocrine tumors.

Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.

Measurement of tissue factor activity in extracellular vesicles from human plasma samples.

Intrinsic Pathway of Coagulation and Thrombosis.

A clinical practice-based evaluation of the RIETE score in predicting occult cancer in patients with venous thromboembolism.

Choosing a Mouse Model of Venous Thrombosis.

Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice.

Choosing a mouse model of venous thrombosis: a consensus assessment of utility and application.

Expression of factor V by resident macrophages boosts host defense in the peritoneal cavity.

Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.

Patients with severe orthohantavirus cardiopulmonary syndrome due to Sin Nombre Virus infection have increased circulating extracellular vesicle tissue factor and an activated coagulation system.

Inflammasome Activation Triggers Blood Clotting and Host Death through Pyroptosis.

Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.

Mitochondria Are a Subset of Extracellular Vesicles Released by Activated Monocytes and Induce Type I IFN and TNF Responses in Endothelial Cells.

Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival.

Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis.

Protease-activated receptor 4 protects mice from Coxsackievirus B3 and H1N1 influenza A virus infection.

Rivaroxaban does not affect growth of human pancreatic tumors in mice.

Increasing the sensitivity of the human microvesicle tissue factor activity assay.

Cell type-specific mechanisms coupling protease-activated receptor-1 to infectious colitis pathogenesis.

How useful are ferric chloride models of arterial thrombosis?

Circulating Extracellular Vesicle Tissue Factor Activity During Orthohantavirus Infection Is Associated With Intravascular Coagulation.

Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX.

Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models.

Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure.

Annual Report on Sex in Preclinical Studies: Publications in 2018.

Differential roles of factors IX and XI in murine placenta and hemostasis under conditions of low tissue factor.

Therapeutic strategies for thrombosis: new targets and approaches.

Quantification of Viral and Host Biomarkers in the Liver of Rhesus Macaques: A Longitudinal Study of Zaire Ebolavirus Strain Kikwit (EBOV/Kik).

Chemotherapy Increases Stroke: Fact or Fiction?

Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer.

Quantification of citrullinated histones: Development of an improved assay to reliably quantify nucleosomal H3Cit in human plasma.

Coagulation Abnormalities and Thrombosis in Patients Infected With SARS-CoV-2 and Other Pandemic Viruses.

Tissue factor in atherosclerosis and atherothrombosis.

Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.

Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.

Model-dependent contributions of FXII and FXI to venous thrombosis in mice.

Description of the first mutation in the human tissue factor gene associated with a bleeding tendency.

Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report.

Circulating Markers of Neutrophil Extracellular Traps Are of Prognostic Value in Patients With COVID-19.

PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus.

New Cellular Source of TF (Tissue Factor)-Positive Extracellular Vesicles in the Circulation.

Elevated factor V activity and antigen levels in patients with Covid-19 are related to disease severity and 30-day mortality.

Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.

The Intrinsic Pathway does not Contribute to Activation of Coagulation in Mice Bearing Human Pancreatic Tumors Expressing Tissue Factor.

Natural IgM antibodies inhibit microvesicle-driven coagulation and thrombosis.

Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge.

Cancer Therapy-Associated Thrombosis.

Platelets and viruses.

Prognostic value of circulating markers of neutrophil activation, neutrophil extracellular traps, coagulation and fibrinolysis in patients with terminal cancer.

Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

COVID-19 is Associated with an Acquired Factor XIII Deficiency.

Effects of storage and leukocyte reduction on the concentration and procoagulant activity of extracellular vesicles in canine packed red cells.

Comparison of the coagulopathies associated with COVID-19 and sepsis.

Myeloid cell-derived coagulation tissue factor is associated with renal tubular damage in mice fed an adenine diet.

Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.

Inflammasome activation promotes venous thrombosis through pyroptosis.

Cardiac Tissue Factor Regulates Inflammation, Hypertrophy, and Heart Failure in Mouse Model of Type 1 Diabetes.

Cell type-specific roles of PAR1 in Coxsackievirus B3 infection.

Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer.

Tissue factor expression, extracellular vesicles, and thrombosis after infection with the respiratory viruses influenza A virus and coronavirus.

Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.

Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.

Platelet-Mediated NET Release Amplifies Coagulopathy and Drives Lung Pathology During Severe Influenza Infection.

Myeloid Protease-Activated Receptor-2 Contributes to Influenza A Virus Pathology in Mice.

Effect of heparanase inhibitor on tissue factor overexpression in platelets and endothelial cells induced by anti-β2-GPI antibodies: Comment from Mackman et al.

Web of Science's Citation Median Metrics Overcome the Major Constraints of the Journal Impact Factor.

Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer: Comment by Mackman et al.

Cancer-associated venous thromboembolism.

Effect of combining aspirin and rivaroxaban on atherosclerosis in mice.

Evaluation of a new bead-based assay to measure levels of human tissue factor antigen in extracellular vesicles in plasma.

Direct Oral Anticoagulants and Coronary Artery Disease.

Methods for the identification and characterization of extracellular vesicles in cardiovascular studies - from exosomes to microvesicles.

Therapeutic potential of granulocyte microvesicles in sepsis.

Anticoagulant SERPINs: Endogenous Regulators of Hemostasis and Thrombosis.

Circulating tissue factor-positive extracellular vesicles and their association with thrombosis in different diseases.

Illustrated State-of-the-Art Capsules of the ISTH 2022 Congress.

Measurement of tissue factor-positive extracellular vesicles in plasma: strengths and weaknesses of current methods.

Markers of neutrophil activation and neutrophil extracellular traps in diagnosing patients with acute venous thromboembolism: A feasibility study based on two VTE cohorts.

Understanding COVID-19-associated coagulopathy.

Hereditary angioedema is associated with an increased risk of venous thromboembolism.

Tissue Factor and COVID-19: An Update.

Neutrophil extracellular traps and cancer-associated thrombosis.

Cardiovascular Disease and Thrombosis in HIV Infection.

Circulating Tumor Cells and Cancer-Associated Venous Thrombosis: A Missing Link.

Thrombin-mediated activation of PAR1 enhances doxorubicin-induced cardiac injury in mice.

A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation.

"Hereditary angioedema is associated with an increased risk of venous thromboembolism": reply.

C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis.

Decreased Platelet Reactivity and Function in a Mouse Model of Human Pancreatic Cancer.

Loss of P2Y receptor desensitization does not impact hemostasis or thrombosis despite increased platelet reactivity in vitro.

"A rapid, sensitive, and specific assay to measure tissue factor activity based on chromogenic determination of thrombin generation": comment from Tanratana et al.

High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism.

Tissue factor activity of small and large extracellular vesicles in different diseases.

Mechanisms of cancer-associated thrombosis.

Tissue factor-positive extracellular vesicles in plasma are not associated with venous thromboembolism in patients with ovarian cancer.

Monocyte Tissue Factor Expression: Lipopolysaccharide Induction and Roles in Pathological Activation of Coagulation.

Evaluation of four commercial ELISAs to measure tissue factor in human plasma.

Detection of tissue factor-positive extracellular vesicles using the ExoView R100 system.

Tissue factor activates the coagulation cascade in mouse models of acute promyelocytic leukemia.

Heat shock protein 47 and venous thrombosis: letting sleeping bears lie.

Neutrophil extracellular trap formation is an independent risk factor for occult cancer in patients presenting with venous thromboembolism.

APC-PAR1-R46 signaling limits CXCL1 expression during poly IC-induced airway inflammation in mice.

"C1-inhibitor levels and Venous Thromboembolism: Results from a Mendelian Randomization Study": comment from Grover et al.

"High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism": reply.

Regulation of von Willebrand factor by ADAMTS13 ameliorates lipopolysaccharide-induced lung injury in mice.

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.

Mice expressing nonpolymerizable fibrinogen have reduced arterial and venous thrombosis with preserved hemostasis.

Biomarkers of bleeding and venous thromboembolism in patients with acute leukemia.

Commentary: Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis.

Tissue factor binds to and inhibits interferon-α receptor 1 signaling.